Everything you need to win Karim Benhadji, M.D. — in one platform.
Who to reach, what to say, and why now on Karim Benhadji, M.D. — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Karim Benhadji, M.D. — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Inspirna Appoints Karim Benhadji, M.D. As Chief Medical Officer
PRIVATEMay 21, 2024•about 2 years ago
Position
Chief Medical Officer
Company
Inspirna
Karim Benhadji, M.D.
New YorkBiotechnology
Description
Inspirna, Inc. has announced the appointment of Karim Benhadji, M.D., as Chief Medical Officer, effective May 1, 2024
Company Information
Company
Inspirna
Location
310 EAST 67TH STREET, SUITE 1-12
New York, New York, United States
About
Inspirna, Inc., is a privately-held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. The company is pursuing several first-in-class drug candidates. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients where it enables the generation of the energy molecule ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer.
New YorkBiotechnology